Vyvanse, or lisdexamfetamine dimesylate, is prescribed to treat attention deficit hyperactivity disorder (ADHD).
Though it is a stimulant drug, children who are diagnosed with the disorder are often better able to quiet their energy and focus on schoolwork.
For those who are not diagnosed with the disorder and for many adults, however, the drug can trigger a response in the body typical of all stimulants.
With continued use, tolerance can develop, which in turn can lead to Vyvanse abuse and addiction when coupled with cravings for more and more of the drug. Once Vyvanse addiction begins, the safe way to manage the issue is to enroll in a comprehensive detox and treatment program.
Vyvanse abuse may be an occasional choice, but when it becomes a daily decision, it can quickly lead to a potentially life-altering addiction.
Ready to get Help?
THINK YOU CAN’T AFFORD TREATMENT? THINK AGAIN! INSURANCE CAN COVER UP TO 100%!
Everyone’s experience with stopping the use of Vyvanse is different. Depending on the dose at the time of detox and any co-occurring mental health or medical disorders, the detox timeline will vary significantly. In general, the longer someone has used the drug and the higher the dose when they stop, the more intense their withdrawal symptoms will be and the longer the process may last.
The first week is considered an acute period of withdrawal. After this point, many people will find that their symptoms begin to subside until they disappear entirely.
Though medical care and extensive monitoring are recommended during the first week, it is also important to note that detox and treatment do not end when withdrawal symptoms stop. This only addresses the physical nature of addiction and does nothing to remove the issues that may have triggered the problem in the first place. Co-occurring mental health disorders, trauma, and more may make it difficult to avoid relapse; for this reason, comprehensive treatment is recommended.
When it is clear that abuse has become an addiction, or when the consequences of a substance use disorder are too overwhelming to ignore, it is time to connect with a detox center that is equipped to fully treat all the issues facing the person in crisis. With so many treatment options to choose from, it is not always easy to identify the program that will be most effective for your needs.
As with the experience of detox and the timeline associated with Vyvanse withdrawal symptoms, no single detox program will work optimally for everyone.
If someone you love is risking their health and wellness with continued use and abuse of Vyvanse, do not wait to reach out and ask for help. Start with your doctor, someone who knows your loved one’s medical and drug history if possible. Ask about what specifics you should look for in a detox program, and make a note of the features and treatment options the doctor suggests.
Next, reach out to your insurance company. Take the time to research your options and determine what it is covered and in what amounts. The more information you have about what you can expect from your insurance company regarding coverage and what you will need to cover out of pocket, the better equipped you will be to choose the best possible detox and treatment program for your loved one.
Finally, make the call. Pick up the phone and speak to a treatment consultant about the types of programs available and what therapies and treatments your loved one can take part in.
Make today the day you reach out for help on behalf of your loved one.
YOU SHOULD CALL THE PALM BEACH INSTITUTE AT (855)-534-3574 TODAY TO SPEAK WITH OUR ADDICTION SPECIALISTS WHO WILL BE AVAILABLE 24/7 TO GUIDE YOU TOWARD THE TREATMENT BEST FIT FOR YOU.
(May 2010) Lisdexamfetamine Dimesylate (Vyvanse), A Prodrug Stimulant for Attention-Deficit/Hyperactivity Disorder. Pharmacy & Therapeutics. from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2873712/
(June 2018) Prescription Stimulants. National Institute on Drug Abuse. from https://www.drugabuse.gov/publications/drugfacts/prescription-stimulants
(September 2012) Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain and Behavior. from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489818/
(September 2016) Prescription Drug Use and Misuse in the United States: Results from the 2015 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. from https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm
Emerging Trends in Prescription Stimulants Indicated for Treatment of Attention-Deficit/Hyperactivity Disorder: Mississippi, 2011 and 2014. Mississippi State Department of Health. from https://msdh.ms.gov/msdhsite/index.cfm/31,7620,382,740,pdf/ADHDPrescriptions2012.pdf
(June 2017) Vyvanse Crash: What It Is and How to Deal with It. Healthline. from https://www.healthline.com/health/adhd/vyvanse-crash#withdrawal
(May 2011) Bulimia Nervosa Among Methamphetamine Dependent Adults: Association With Outcomes 3 Years After Treatment. Eating Disorders. from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159413/
(2008) Substance Use Disorders in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Implications for Treatment and the Role of the Primary Care Physician. The Primary Care Companion to the Journal of Clinical Psychiatry. from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446489/
(September 2013) Assessing prescription stimulant use, misuse and diversion among youth 10 to 18 years of age. Current Opinion in Psychiatry. from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832028/
(January 2016) ADHD-specific stimulant misuse, mood, anxiety, and stress in college-age women at high risk for or with eating disorders. Journal of American College Health. from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904716/
Vyvanse (lisdexamfetamine dimesylate). U.S. Food and Drug Administration. from https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf
(April 2018) Coping with a Vyvanse Crash. Medical News Today. from https://www.medicalnewstoday.com/articles/321489.php